Antifungal Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 244 of the 250 references it cites were found in a registry or an index.
Abstract
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been attributed to non-mycologic causes such as host factors, immune status, and/or pharmacologic issues8.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
In the citing paper
“it leaves the polyene amphotericin B, which is toxic8, as the only treatment option for these infections.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · cited 2×
“…of cryptococcal meningitis 14 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg (Perfect et al. 2010), and, until recently, although clinical efficacy was clear with this strategy, formal PK/PD studies were lacking for this…”
BackgroundRex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,556
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“From a pharmacodynamic (PD) perspective, PK measures represent drug exposure with respect to the host, for example, translating a dose (i.e., mg/kg) to a drug exposure (e.g., area under the concentration curve, or AUC) (Drusano 2004).”
BackgroundPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 1×
“Study from two phase 3 clinical trials of micafungin use in patients with candidemia or invasive candidiasis was recently used for PK/PD analysis (Andes et al. 2012).”
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176
“Readers are referred to excellent reviews on these topics [50,51].”
BackgroundIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144
“and interact with other drugs such as chemotherapy agents and immunosuppressants (4).”
BackgroundDefining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Metadata
- Authors
- Lepak, A. J., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-11-10
- Volume
- 5
- Issue
- 5
- Pages
- a019653-a019653
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC4448584
- OpenAlex
- W2106743979
- Cited by
- 134
- References
- 250
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 14 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 2 · 2015: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, pharmacokinetics, pharmacodynamics, pharmacokinetic-pharmacodynamic modeling, polyenes, 5-fluorocytosine, azoles, echinocandins, dosing regimen, susceptibility breakpoints, combination antifungal therapy, drug toxicity
- MeSH terms
- Animals, Antifungal Agents, Disease Models, Animal, Flucytosine, Humans, Mycoses, Polyenes, Rabbits, Triazoles, Mice, Rats, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal Pharmacokinetics and Pharmacodynamics. https://app.cochat.ai/papers/10.1101/cshperspect.a019653
- The paper
- Lepak, A. J., & Andes, D. R. (2015). Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a019653
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.